An expert presents the results of a phase 2 study on the impact of rituximab on myasthenia gravis.
An expert describes the efficacy of fenfluramine in decreasing seizure frequency associated with this rare syndrome.
A unique case of chronic, low level carbon monoxide poisoning in a car mechanic that resulted in Parkinsonian symptoms.
The presence of REM Behavior Disorder predicted an increased risk of Parkinson disease, Lewy Body dementia, or multisystem atrophy in the largest study ever performed in people with the strange disorder. Details here.
It looks like research is starting to support exercise as a reliable strategy to prevent dementia.
The finger displacement sign is a simple bedside test that can help distinguish Parkinson dementia from Alzheimer dementia.
Chronic traumatic encephalopathy is a neurodegenerative disease that is believed to be a consequence of exposure to repetitive head impacts, including concussions and subconcussive injuries.
New research highlights the need for early identification of traumatic brain injury as well as an interdisciplinary approach to determining treatment strategies.
A new class of injectable monoclonal antibodies directed against calcitonin gene related peptide (CGRP) or its receptor may offer hope to migraineurs who have not found effective prophylactic therapy.
When and why were the Beers criteria set in place? Learn more in this quiz.
Noninvasive neuromodulation therapy shows promise in treating hand tremors associated with essential tremor.
Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.
Ondine’s curse has long been recognized as a congenital disorder and can also develop later in life as a result of damage to the lower lateral medulla. There are only a few cases—about 200 to 500 worldwide—each year.
Neurologists may be the first or only clinicians to recognize the 5 potentially dangerous neuro-ophthalmologic conditions described in this article.
Findings from a new study indicate that compared with children who were not exposed to the drug, children with in utero exposure to sodium valproate have lower scores on national tests at age 7 years.